MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at upcoming conferences.
- Rodman & Renshaw Annual Global Investment Conferenceon Thursday, September 10, 2009 at 11:40 AM (EDT) at the New York Palace Hotel in New York
- Morgan Stanley Global Healthcare Conferenceon Tuesday, September 15, 2009 at 3:20 PM (EDT) at the Grand Hyatt Hotel in New York
- UBS Global Life Sciences Conferenceon Tuesday, September 22, 2009 at 11:00 AM (EDT) at the Grand Hyatt Hotel in New York
Interested parties can access a link to the live webcast of each presentation from the News & Events section of the Company''s website at http://www.mannkindcorp.com. Replays of each presentation will be available for 14 days.
About MannKind Corporation
MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its pipeline includes AFRESA®, MKC253, MKC1106-PP, and MKC1106-MT. MannKind has submitted an NDA to the FDA requesting approval of AFRESA for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. Its other programs are currently in Phase 1 clinical trials. MannKind maintains a website at http://www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.
Contacts:
MannKind Corporation
Matthew J. Pfeffer
Corporate Vice
President and
Chief Financial Officer
661-775-5300
mpfeffer@mannkindcorp.com
